Geredeli, CaglayanYasar, NurgulSakin, Abdullah2025-05-102025-05-1020192090-31702090-318910.1155/2019/96451472-s2.0-85060092227https://doi.org/10.1155/2019/9645147https://hdl.handle.net/20.500.14720/15839Sakin, Abdullah/0000-0003-2538-8569; Geredeli, Caglayan/0000-0002-3982-7465Background. The guidelines recommend considering the BRCA1 and BRCA2 germline mutations in female patients with breast carcinomas. In this retrospective study, the BRCA1/2 mutation prevalence in high-risk breast carcinoma patients in a Turkish population was investigated. Materials and Methods. In high genetic risk breast carcinoma patients, the BRCA1 and BRCA2 germline mutations were identified by applying next-generation sequencing. Results. The results showed BRCA1/2 mutations in 19% of the total patients. In those with first-degree relatives with breast carcinoma histories, the BRCA1/2 mutation prevalence was also 19%. In the patients younger than 40 years old, the BRCA1/2 mutation prevalence was 19.5%. In the triple-negative breast carcinoma patients younger than 60 years old, the BRCA1/2 mutation prevalence was 24.2%. In the patients younger than 40 years old with triple-negative breast carcinomas, BRCA1/2 mutation positivity was found in 37.5% of the patients. Overall, in the Turkish population, the BRCA1/2 mutation prevalence ranges from 19% to 37% in patients with high-risk breast carcinomas. Conclusion. It is recommended to check for BRCA1/2 mutations in all high-risk breast carcinoma patients in the Turkish population.eninfo:eu-repo/semantics/openAccessArticle2019N/AQ330713775WOS:000455758300001